The Hematologist

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Support for this episode provided by Autolus.

In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Excellence. They talk about a systematic literature review, led by Dr. DeBaun and published in the journal Blood, that found no link between sickle cell trait and sudden death – a finding that challenges a long-standing myth about the trait. Support for this episode provide by Siemens Healthineers.

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School. They talk about the use of Glofit-GemOx in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Support for this episode provided by Autolus.

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine at Stanford University where she focuses on cellular therapy for adults with acute leukemia, talks with Steven Devine, MD, the chief medical officer at the National Marrow Donor Program. They talk about the rise of HLA-mismatched unrelated donor transplants in the U.S.

In this episode, Contributing Editor Brian Hill, MD, PhD, director of the lymphoid malignancies program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, talks with Tim Fenske, MD, who at the time of this recording was joining the transplant and cell therapy group at Sarah Cannon Methodist Healthcare in San Antonio, Texas. Dr. Fenske previously led the lymphoma program at the Medical College of Wisconsin. They talk about a new study that found a lack of benefit in autologous stem cell transplantation for patients with mantle cell lymphoma.

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.” 

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina Chapel Hill, talks with Adetola Kassim, MD, a professor of medicine in the division of hematology and oncology at Vanderbilt University Medical Center. They talk about a recent paper co-authored by Dr. Kassim: “An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease.”

In this episode, Contributing Editor Lauren Pommert, MD, a pediatric oncologist specializing in children with leukemia at Cincinnati Children's in Cincinnati, Ohio, talks with Natalie DelRocco, PhD, a senior statistician for the Children’s Oncology Group’s Bone Tumors Committee and an assistant professor of clinical population and public health sciences in the Division of Biostatistics at the University of Southern California in Los Angeles. They talk about a recent paper co-authored by Dr. DelRocco: “Enhanced Risk Stratification for Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report.”

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Martin Dreyling, MD, a professor of medicine and head of the lymphoma program at LMU Hospital in Munich. They discuss the TRIANGLE trial, conducted by Dr. Dreyling and colleagues, for the European Mantle Cell Lymphoma Network. 

In this episode, Contributing Editor Surbhi Shah, MD, a classical hematologist at Mayo Clinic in Phoenix, leads a conversation about anticoagulation stewardship. Her guests are Allison Burnett, PharmD, PhC, an antithrombosis stewardship pharmacist at the University of New Mexico Hospital and president of the Anticoagulation Forum, and Geoffrey Barnes, MD, MSc, an associate professor and vascular medicine specialist at the University of Michigan and president-elect of the Anticoagulation Forum.

In this episode, Editor-in-Chief Shaji Kumar, MD,  a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Jorge Cortes, MD, the inaugural editor-in-chief of Blood Global Hematology, one of the latest additions to the growing Blood journals portfolio. Dr. Cortes, director of the Georgia Cancer Center at Augusta University, shares his vision for the journal and his thoughts on how it will impact the hematologic research community around the world. Support for this episode provided by Rigel Pharmaceuticals.

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapy at Stanford University in California, talks with Fred Appelbaum, MD, executive vice president and deputy director at the Fred Hutchinson Cancer Center in Seattle, and a professor of medicine in the division of hematology and oncology at the University of Washington. They talk about Dr. Appelbaum’s book, Living Medicine: Don Thomas, Marrow Transplantation, and the Cell Therapy Revolution.

In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently published in Cancer Discovery: “JAK2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms.”

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon titled, “Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.” Dr. Wilson wrote about the study in a recent issue of The Hematologist.

In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of trainees into hematology. Dr. Ellis is chair of an ASH oversight subcommittee for that program.